Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Advances in the use of topical imiquimod to treat dermatologic disorders

Authors Lacarrubba F, Nasca MR, Micali G

Published 8 February 2008 Volume 2008:4(1) Pages 87—97


Francesco Lacarrubba, Maria Rita Nasca, Giuseppe Micali

Dermatology Clinic, University of Catania, Italy

Abstract: Imiquimod (IQ) is an immune-response modifying agent, first approved by FDA for the topical treatment of external genital and perianal warts in 1997. It induces, through stimulation of Toll-like receptors (TLRs) localized on the surface of antigen-presenting cells, synthesis and release of several endogenous pro-inflammatory cytokines such as interferon-α (IFN-α), tumor necrosis factor-α (TNF-α) and interleukins (IL) 6 and 12, which in turn stimulate both the innate and acquired immune pathways, resulting in upregulation of natural antiviral and antitumor activity. IQ 5% cream has been used for the treatment of a wide variety of dermatologic conditions in which the immune system is thought to play a role in regression of the disease. In some disorders, such as genital and perianal warts, actinic keratoses, basal cell carcinomas, Bowen’s disease and molluscum contagiosum, relative safety and efficacy are supported by randomized controlled trials of IQ. However, it is common for patients to experience local skin reactions, which can range from mild to severe in intensity, but usually resolve 1–2 weeks after interrupting treatment. Additional randomized trials are encouraged to assess safety and efficacy of IQ in the treatment of an even wider range of cutaneous disorders.

Keywords: imiquimod, immune response modifiers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Nurse home visits with or without alert buttons versus usual care in the frail elderly: a randomized controlled trial

Favela J, Castro LA, Franco-Marina F, Sánchez-García S, Juárez-Cedillo T, Espinel Bermudez C, Mora-Altamirano J, Rodriguez MD, García-Peña C

Clinical Interventions in Aging 2013, 8:85-95

Published Date: 23 January 2013

A review of topotecan in combination chemotherapy for advanced cervical cancer

Minoo Robati, David Holtz, Charles J Dunton

Therapeutics and Clinical Risk Management 2008, 4:213-218

Published Date: 8 February 2008

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

Martin Henkes, Heiko van der Kuip, Walter E Aulitzky

Therapeutics and Clinical Risk Management 2008, 4:163-187

Published Date: 8 February 2008

Trabectedin and its potential in the treatment of soft tissue sarcoma

Philippe A Cassier, Armelle Dufresne, Jean-Yves Blay, Jérôme Fayette

Therapeutics and Clinical Risk Management 2008, 4:109-116

Published Date: 8 February 2008

A review of solifenacin in the treatment of urinary incontinence

Ramandeep Basra, Con Kelleher

Therapeutics and Clinical Risk Management 2008, 4:117-128

Published Date: 8 February 2008

Management of laryngopharyngeal reflux with proton pump inhibitors

Christina Reimer, Peter Bytzer

Therapeutics and Clinical Risk Management 2008, 4:225-233

Published Date: 8 February 2008

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

Lala M Dunbar, Derek M Tang, Robert M Manausa

Therapeutics and Clinical Risk Management 2008, 4:235-244

Published Date: 8 February 2008